Welcome to our dedicated page for Beyond Air news (Ticker: XAIR), a resource for investors and traders seeking the latest updates and insights on Beyond Air stock.
Beyond Air Inc (NASDAQ: XAIR) is a clinical-stage medical technology company pioneering nitric oxide delivery systems for respiratory care. This news hub provides investors and healthcare professionals with essential updates on regulatory milestones, clinical trial progress, and technological advancements related to the LungFit™ platform.
Access timely press releases covering FDA communications, partnership announcements, and research developments in pulmonary hypertension treatment. Our curated collection includes updates on international regulatory strategies and peer-reviewed study publications, offering critical insights into the company's position within the respiratory therapy market.
Key content categories include clinical trial results, device approval updates, executive leadership changes, and scientific conference presentations. This resource enables stakeholders to track the company's progress in developing NO-based solutions for ventilator-associated pneumonia and chronic lung conditions.
Bookmark this page for streamlined access to material developments affecting XAIR's market position. For comprehensive analysis of how these updates may influence investment decisions, consult your financial advisor and review official SEC filings.
Beyond Air (NASDAQ: XAIR) appointed Dan Moorhead as Chief Financial Officer, effective January 5, 2026. Duke Dewrell will resume his prior role as Controller on that date.
Mr. Moorhead brings >20 years of finance leadership, including serving as CFO of Zynex from June 2017 to August 2025. The company granted an inducement option exercisable for 70,000 shares, effective January 5, 2026, with a 10-year term and four-year vesting (25% after one year, then annual thirds). The exercise price equals the last reported Nasdaq sale price on December 31, 2025. The award was approved by the independent compensation committee and is subject to the company's equity incentive plan.
Beyond Air (NASDAQ: XAIR) announced new international distribution agreements for LungFit PH adding Germany, Brazil, Austria, the Netherlands and Sri Lanka and expanding its network to 39 countries.
The agreements cover a combined population of more than three billion people. Beyond Air said some markets will require regulatory approvals that may take time, while others are expected to begin benefiting from LungFit PH in calendar 2026. LungFit PH generates nitric oxide from ambient air, providing a tankless alternative to high‑pressure cylinders intended to streamline hospital operations, improve efficiency and reduce environmental impact.
Beyond Air (NASDAQ: XAIR) announced that Chief Financial Officer Doug Larson resigned to pursue another opportunity and will remain CFO through December 5, 2025. Controller Duke Drewell will assume CFO responsibilities on an interim basis while the company has launched a search for a permanent successor. Mr. Larson will continue in an advisory role through calendar year-end 2025. The company credited Larson with helping the business transition to commercial operations, including the launch of LungFit PH and majority-owned subsidiaries Beyond Cancer and NeuroNOS, and said recent financing agreements strengthened the balance sheet. The departure was stated not to result from any disagreements over financial reporting or policies.
Beyond Air (NASDAQ: XAIR) reported fiscal Q2 2026 results for the quarter ended September 30, 2025 with revenue +128% YoY to $1.8M and an updated fiscal 2026 revenue guidance of $8–$10M. The company closed a financing providing a $12.0M promissory note plus an equity line up to $20M, yielding a proforma cash balance of $22.9M and runway into calendar 2027. Net loss was $7.9M (–$1.25 per share), net cash burn was $4.7M for the quarter, and reported cash and marketable securities were $10.7M with long-term debt of $10.1M. Commercially, LungFit PH expanded to 35 countries, MDSAP certification was achieved, and a PMA supplement for second-generation LungFit PH was submitted in June 2025. Bob Goodman named interim Chief Commercial Officer.
Beyond Air (NASDAQ: XAIR) entered financing agreements with Streeterville Capital providing up to $32 million in potential proceeds: a $12 million promissory note and a $20 million equity line of credit (ELOC). Pro forma cash, cash equivalents, restricted cash and marketable securities totaled $22.9 million as of September 30, 2025, which includes the $12 million note. The promissory note bears 15% annual interest, matures in 24 months with no payments for the first 12 months, and places $6 million in a restricted account. The ELOC allows sale of up to $20 million of common stock over 24 months and requires an S-1 resale registration. Management says the financing extends runway into calendar 2027 and supports LungFit PH commercial expansion and a planned second-generation launch before end of 2026.
Beyond Air (NASDAQ: XAIR) will release second fiscal quarter 2026 financial results for the period ended September 30, 2025 on Monday, November 10, 2025. The company's management will host a conference call and webcast the same day at 4:30 PM Eastern Time to discuss results.
Dial-in details: Domestic 1-877-407-0784, International 1-201-689-8560, Conference ID 13756730. A live webcast will be available in the Events section of the company's website, and an online replay will be posted about one hour after the call.
Beyond Air (NASDAQ: XAIR), a commercial stage medical device and biopharmaceutical company specializing in nitric oxide (NO) treatments, announced its participation in the ROTH 4th Annual Healthcare Opportunities Conference. The event will take place on October 9, 2025, in New York, NY.
The company's Chief Financial Officer, Douglas Larson, will be available for one-on-one meetings with investors during the conference. Interested investors can schedule meetings through their Roth Capital Partners representatives.
Beyond Air (NASDAQ: XAIR) has secured approximately $3.25 million in gross proceeds through the exercise of existing warrants. The agreement involves the immediate exercise of warrants to purchase 1,439,126 shares of common stock at a reduced price of $2.21 per share.
As part of the transaction, the company will issue new unregistered warrants to purchase up to 719,561 shares of common stock at $0.0625 per warrant. These new warrants will have an exercise price of $2.21 per share, with immediate exercisability and a five-year term. The proceeds will support Beyond Air's clinical and pre-clinical programs, operating expenses, and working capital.
NeuroNOS, a subsidiary of Beyond Air (NASDAQ: XAIR), has received FDA Orphan Drug Designation (ODD) for its lead therapy BA-101 in treating Glioblastoma (GBM), an aggressive brain cancer. This marks the company's second ODD and its entry into oncology.
GBM currently has limited treatment options with median survival less than 12 months, and survival rates of less than 20% at two years and less than 10% at five years. The ODD grants several benefits, including seven years of market exclusivity, tax credits for clinical trials, and prescription drug user fee waivers.
The company's approach focuses on NO inhibition strategy, supported by research showing nitric oxide as an important modulator in GBM treatment response.
Beyond Air (NASDAQ: XAIR), a commercial stage medical device and biopharmaceutical company specializing in nitric oxide (NO) treatments, announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York.
Chairman and CEO Steve Lisi will represent the company, with an on-demand presentation webcast available starting September 5, 2025, at 7:00 a.m. ET. Management will also be available for one-on-one investor meetings during the conference.
FAQ
What is the current stock price of Beyond Air (XAIR)?
What is the market cap of Beyond Air (XAIR)?
